| Market Cap | 10.87M | P/E | - | EPS this Y | 70.60% | Ern Qtrly Grth | - |
| Income | -8.7M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 1.84M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
| Dividend | N/A | Price/Book | 0.88 | EPS next 5Y | - | 52W High Chg | -36.00% |
| Recommedations | 2.00 | Quick Ratio | 0.42 | Shares Outstanding | 144.20M | 52W Low Chg | 44.00% |
| Insider Own | 24.34% | ROA | -74.79% | Shares Float | 112.09M | Beta | 1.12 |
| Inst Own | 0.10% | ROE | -212.20% | Shares Shorted/Prior | -/- | Price | 0.08 |
| Gross Margin | -178.04% | Profit Margin | - | Avg. Volume | 19,270 | Target Price | 2.00 |
| Oper. Margin | -140.94% | Earnings Date | Nov 12 | Volume | 21,390 | Change | 4.75% |
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.
